Page 1

Teleflex® FOR IMMEDIATE RELEASE TELEFLEX REPORTS THIRD QUARTER 2021 RESULTS AND FULL YEAR OUTLOOK Wayne , PA -- Teleflex Incorporated ( NYSE : TFX ) ( the " Company " ) today announced financial results for the third quarter ended September 26 , 2021 . Third quarter financial summary . Reported revenues of $ 700.3 million , up 11.5 % year - over - year ; up 10.3 % on a constant currency basis GAAP diluted EPS from continuing operations of $ 4.20 as compared to $ 2.46 in the prior year period Exhibit 99.1 October 28 , 2021 Adjusted diluted EPS from continuing operations of $ 3.51 , up 26.7 % year - over - year 2021 guidance summary GAAP revenue growth decreased to 10.00 % to 11.00 % due to greater than anticipated headwinds from COVID - 19 Constant currency revenue growth reduced to 8.00 % to 9.00 % from 8.50 % to 9.75 % previously GAAP diluted EPS increased to $ 9.86 to $ 10.06 from $ 9.50 to $ 9.60 previously , and adjusted diluted EPS raised to $ 13.15 to $ 13.35 from $ 12.90 to $ 13.10 previously Liam Kelly , Chairman , President and Chief Executive Officer , said , " Teleflex delivered solid third quarter results reflecting the benefits of our diversified product portfolio and disciplined operating execution , despite varying levels of headwinds associated with COVID - 19 infections across our product lines and geographic segments . In the quarter , we generated double - digit constant currency revenue growth and a sequential improvement in operating margin , which led to $ 3.51 in adjusted EPS , up 27 % year - over - year . UroLift witnessed a greater than expected impact from COVID - 19 during the third quarter , including regional pauses in elective surgical procedures and business - related disruptions associated with the pandemic . For 2021 , we are lowering our constant currency revenue guidance range and raising the full year adjusted earnings per share guidance range . Given our third quarter results and fourth quarter outlook , our 2021 revenue growth guidance for UroLift has been reduced to 15-17 % year - over - year . Our revised outlook does not assume a full recovery in elective surgical procedures due to the ongoing impact of the COVID - 19 pandemic . " 1